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Abstract
Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei
parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it
may take several months after treatment before surviving parasites become detectable in the blood. To
expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing
red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive whole-
body bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging
of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the
hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).
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1 Introduction
Human African trypanosomiasis (HAT), also called sleeping sick-
ness, occurs in two clinical stages: a hemolymphatic phase (stage 1),
where parasites are detected in blood and lymph, and an encepha-
litic phase (stage 2) involving the central nervous system (CNS).
Established mouse models for HAT rely on detection of blood
parasites, usually of monomorphic T. brucei strain Lister 427 during
the first few days of infection (to mimic stage 1 disease), and of
pleomorphic T. brucei strain GVR35 after 21 days of infections
(to mimic stage 2 disease) [1, 2]. This involves sampling of blood
for parasite detection by light microscopy and does not allow real-
time detection of parasites that are extravascular and within tissues
such as the spleen, lymph nodes, adipose tissue, and brain.
In vivo imaging is highly sensitive, noninvasive, and quantifi-
able, and has become an indispensable and valuable tool for the
monitoring of disease progression in live animals. This technology
has been applied to investigate infection dynamics and to screen
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drugs against Plasmodium spp. [3–5], Mycobacterium tuberculosis
[6], Leishmania spp. [7, 8], Trypanosoma cruzi [9], and Trypano-
soma brucei [10, 11]. To make use of this technology for the
screening of novel trypanocidal compounds, bioluminescent Try-
panosoma brucei brucei cell lines were generated [12, 13] and an
imaging method that is highly sensitive, reproducible and expedites
the screening process was developed [14]. The optimized biolumi-
nescence imaging model using T. b. brucei GVR35 expressing
red-shifted firefly luciferase has been valuable for the identification
of novel compounds against stage 2 HAT [15]. This biolumines-
cence GVR35 model can also be utilized to screen for in vivo
activity during stage 1 disease. Infection of mice with pleomorphic
T. brucei strains is characterized by waves of parasitemia that can be
difficult to detect in the blood. However, sensitive bioluminescence
imaging tracks live parasites over the whole body making it possible
to assess compound activity even with fluctuating and low blood
parasitemia. Using one parasite strain and method to screen for
both stage 1 and 2 efficacy saves limited time and resources rou-
tinely spent to assess compounds in multiple parasite strains and
infection models.
In this protocol, we describe the generation and testing of
bioluminescent T. b. brucei GVR35 stabilates to be used for repro-
ducible infections of mice. We describe the imaging model (Fig. 1)
for screening of compounds against pleomorphic T. b. brucei
GVR35 during stage 1 (day 7 postinfection) or stage 2 (day 21 post-
infection) trypanosomiasis. We provide details on infection of
donor and experimental mice, bioluminescence imaging of mice
(using the IVIS imaging system from PerkinElmer), determination
of blood parasitemia, treatment of mice with compounds, blood
sampling for pharmacokinetic analysis and end-point imaging and







2.1.1 Culturing of T. b.
brucei GVR35 Bloodstream
form Trypanosomes
1. Trypanosoma brucei brucei GVR35-VSL2 [12] (see Note 2).
2. IMDM (Iscove’s Modified Dulbecco’s Medium, Gibco) sup-
plemented with 20% heat-inactivated fetal calf serum, 20%
Serum Plus, 0.75 mM hypoxanthine in 0.1 N NaOH,
4.1 mM glucose, 0.12 mM thymidine, 1.5 mM sodium pyru-
vate, 0.037 mM bathocuproine disulfonic acid, 0.2 mM
β-mercaptoethanol, 1.1 mM L-cysteine, 0.38 mM adenosine,
0.38 mM guanosine, 0.83 g/L methylcellulose, 0.04 mM
kanamycin, 75 units/mL penicillin, and 0.075 mg/mL strep-
tomycin (all Sigma-Aldrich), pH 7.4.
3. 25 cm3 vented flasks.
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2.1.2 Generation
of Bioluminescent T. brucei
Stabilates
1. Trypanosome dilution buffer (TDB): 20 mM Na2HPO4,
2 mM NaH2PO4.2H2O, 80 mM NaCl, 5 mM KCl, 1 mM
MgSO4.7H2O, 20 mM D-glucose, pH 7.4.
2. Adult, female CD1 (ICR) mice (~25 g body weight) main-
tained under specific pathogen free conditions (see Note 3).
3. 1 mL syringes and 25 G needles.
4. 0.9% NH4Cl.
5. Blood lancets.
6. CBSS heparin solution: 25 mM HEPES, 120 mM NaCl,
5.4 mM CaCl2∙H2O, 0.5 mM MgSO4∙7H2O, 5.6 mM
Na2HPO4, 11.1 mM D-glucose, pH 7.4, 10 units heparin/mL.
7. Light microscope and hemocytometer within the animal
facility.
8. CO2 euthanasia apparatus.
9. Fine bore polythene tubing (0.58 mm internal diameter,
0.96 mm external diameter).
10. Monoject aluminum hub blunt needles (0.6 mm  25.4 mm).
11. Cryovial tubes.
12. Glycerol.
13. “Mr frosty” freezing container.
Fig. 1 Schematic of the T. brucei brucei GVR35-VSL2 imaging model. CD1 mice are infected with 3  104
bloodstream form T. b. brucei GVR35-VSL2 and treated with compounds from day 7 (d7) or day 21 (d21)
postinfection to screen for activity during stage 1 or stage 2 trypanosomiasis, respectively. Whole body
bioluminescence imaging is performed using an IVIS imaging system before treatment and daily (stage 1) or
weekly (stage 2) after treatment to monitor parasite burden
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2.1.3 Testing
of Bioluminescent T. brucei
Stabilates
1. Trypanosoma brucei brucei GVR35-VSL2 [12] blood straws
(see Subheading 3.1.2).
2. Trypanosome dilution buffer (TDB) (see Subheading 2.1.2).
3. Adult, female CD1 mice (~25 g body weight) maintained
under specific pathogen free conditions (see Note 3).
4. 0.9% NH4Cl.
5. Blood lancets.
6. 1 mL syringes and 25 G needles.
2.2 In Vivo Imaging
Model
2.2.1 Infection of Donor
and Experimental Mice
l Adult, female CD1 mice (~25 g body weight) maintained under
specific pathogen free conditions (see Note 3).
l Blood straws of T. b. brucei strain GVR35-VSL2 (red-shifted)
luciferase expressing cell line (see Subheading 3.1.2).
l Trypanosome dilution buffer (TDB) (see Subheading 2.1.2).
l CBSS heparin solution (see item 7 in Subheading 2.1.1).
l 0.9% NH4Cl.
l Blood lancets.
l 1 mL syringes and 25 G needles.
l Light microscope and hemocytometer in the animal facility.
l CO2 euthanasia apparatus.
l Ear punch tool.
2.2.2 Bioluminescence
Imaging
1. IVIS spectrum In Vivo Imaging System from PerkinElmer (see
Note 4).
2. MgCl2 and CaCl2 free Dulbecco’s PBS purchased from Gibco.
3. Beetle luciferin potassium salt (1 g) from Promega—Prepare
15 mg/mL working stock by resuspending 1 g beetle luciferin
(D-luciferin) potassium salt in 66.66 mL of MgCl2 and CaCl2
free Dulbecco’s PBS, freeze 1 mL aliquots at 20 C.
4. Isoflurane gaseous anesthesia equipment including gas vapor-
izer, scavenger, and oxygen generator (e.g., XGI-8 Gas Anes-
thesia System connected to an oxygen tank or generator).
5. Lacri-Lube ocular lubricant from Allergan pharmaceuticals.






3. Light microscope and hemocytometer in the animal facility.
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2.2.4 In Vivo Compound
Treatments
1. Diminazene aceturate (control treatment).
2. Distilled H2O to solubilize diminazene aceturate.
3. 0.22 μm syringe filters.
4. 1 mL syringes.
5. Mouse feeding tubes—plastic or metal.
6. Lacri-Lube ocular lubricant from Allergan pharmaceuticals.
7. PBS-G: MgCl2 and CaCl2 free Dulbecco’s PBS with 10 mM
glucose, pH 7.4.






2. Thermostatically controlled heated chamber.
3. Mouse restraining apparatus.
4. Heparinized tubes.
5. Screwcap sample tubes.
6. Antimicrobial solution (e.g., chlorhexidine).
2.2.6 End Point Imaging 1. In Vivo Imaging System (IVIS).
2. Beetle luciferin (D-luciferin), 15 mg/mL working stock (see
item 3 in Subheading 2.2.2).
3. PBS-G: MgCl2 and CaCl2 free Dulbecco’s PBS with 10 mM










The bioluminescence imaging model requires infection of donor
mice from T. brucei blood stabilates. These blood stabilates can be
generated from cultured parasites (Subheadings 3.1.1 and 3.1.2) or
from F1 blood stabilate stocks that should be tested (Subheading
3.1.3) and then used for infection and generation of new blood
stabilates (Subheading 3.1.2 from step 5 onward) (see Note 5).
3.1.1 Culturing of
T. b. brucei GVR35-VSL2
Bloodstream form
Trypanosomes
1. Defrost a culture stabilate of T. b. brucei GVR35-VSL2 blood-
stream form trypanosomes [12] and transfer the cell suspen-
sion to a 25 cm3 vented flask containing 10 mL pre-warmed
supplemented IMDM medium.
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2. Leave to recover for around 72 h by culturing cells in vitro at
37 C, 5% CO2 in an upright flask.
3. Count cells and subpassage in supplemented IMDM to
5  104 cells/mL (see Note 6).
4. Following the first passage, count cells every 3–4 days and
subpassage to ensure that the culture is maintained between
5  104 and 1  106 cells/mL (see Note 7).
5. Keep in vitro culture to a minimum to avoid effects on
virulence.
3.1.2 Generation
of Bioluminescent T. brucei
Blood Stabilates
1. For infection from cultured parasites: Count cells of a log-stage
T. b. brucei GVR35-VSL2 culture (between 5  105 and
1  106 cells/mL) to determine cell density.
2. Transfer 5  105 cells to a sterile tube, add 5 mL trypanosome
dilution buffer (TDB) and centrifuge at 1500 g for 10 min at
room temperature.
3. Carefully remove supernatant, repeat centrifugation as above in
5 mL fresh TDB.
4. Carefully remove supernatant, leaving ~500 μL in tube. Resus-
pend pellet in remaining TDB, count cells and adjust final
concentration to 1.2  105 parasites/mL. Proceed to step 6.
5. For infection from blood stabilates: Defrost required amount of
F2 blood straws for infection of two donor mice (determined in
Subheading 3.1.3) into 500 μL TDB and mix well.
6. Inject two CD1 mice intraperitoneally with 250 μL (3  104
parasites) per mouse using a 1 mL syringe and 25 G needle (see
Note 8).
7. Monitor parasitemia of infected mice daily as follows: Dilute
4 μL of blood (taken via a tail vein venipuncture using a lancet
or needle, seeNote 9) in 16 μL of 0.9% ammonium chloride to
lyse the blood cells. Determine parasite density in blood by
counting on a hemocytometer.
8. When parasitemia reaches the first peak (~1  107 parasites/
mL) cull the mouse by exposure to CO2 in a rising concentra-
tion, and remove all blood by cardiac puncture using a syringe
pre-loaded with 200 μL of CBSS heparin buffer (this prevents
coagulation of the blood) (see Note 10).
9. Add 71.4 μL of glycerol to every 500 μL of blood and mix with
a vortex.
10. Using a 1 mL syringe and blunt needle inject blood/glycerol
mix into fine bore polythene tubing and cut into ~2.5 cm
sections, placing “blood straws” into cryovials.
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11. Place cryovials in a “Mr Frosty” or cotton wool lined box and
freeze at 80 C overnight before transferring to liquid nitro-
gen for long-term storage (this is designated as the F1 storage
stock).
3.1.3 Testing
of Bioluminescent T. brucei
Stabilates
1. Remove three frozen straws from liquid nitrogen and dilute in
500 μL TDB.
2. Count parasites with a hemocytometer to calculate the parasite
number in one straw and the number of straws required to
achieve a count of 1.2  105 parasites/mL.
3. Inject 250 μL (3  104 parasites) into a CD1 mouse by intra-
peritoneal injection.
4. Monitor parasitemia daily to calculate the length of time before
the first parasitemia peak.
5. A second stock of blood straws (F2 working stocks) should be
made from the F1 stock as in Subheading 3.1.2 (steps 5–11)—
this F2 stock should also be tested as above and used for
infections of donor mice for reproducible infections.
3.2 In Vivo Imaging
Model
3.2.1 Infection of Donor
and Experimental Mice
1. Select appropriate infection day of donor mice based on when
mice are expected to develop the first peak of parasitemia
(determined in Subheading 3.1.3) (see Note 11).
2. Defrost required amount of F2 blood straws for infection of
two donor mice (determined in Subheading 3.1.3) into 500 μL
TDB and mix well.
3. Inject each mouse intraperitoneally with 250 μL of
TDB/blood straw mixture.
4. Monitor parasitemia daily as described in Subheading 3.1.2
(step 7) until the first peak of parasitemia is achieved
(5  106–1.0  107 parasites/mL).
5. Harvest blood by cardiac puncture under terminal anesthesia
using a syringe prefilled with 200 μL of CBSS heparin to
prevent coagulation of the blood.
6. Determine the blood parasitemia and dilute blood with CBSS
heparin to achieve a concentration of 1.2  105 parasites/mL
before injecting each experimental mouse with 250 μL
(3  104 parasites/mouse).
7. Ear mark mice for identification and weigh all mice.
8. Assign mice to treatment groups (see Note 12).
3.2.2 Bioluminescence
Imaging (See Note 4)
1. At day 7 (stage 1 model) or day 21 (stage 2 model) postinfec-
tion (seeNote 13) image mice before treatment using the IVIS
spectrum as described below. Posttreatment imaging should be
done daily or weekly after start of treatment (see Note 14).
Determine blood parasitemia (see Subheading 3.2.3) on the
same day as imaging.
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2. Defrost the appropriate number of beetle luciferin (15 mg/mL
working stock) vials (10 μL/g of mouse is required).
3. Start the Living Image software. Enter initials or select from
the list when prompted to do so by the software.
4. Create an appropriate folder on the computer hard drive to save
the data generated.
5. Once the program opens initialize the system using the “Ini-
tialize” tab in the bottom right corner of the control panel
(Fig. 2).
6. Once the system is initialized the “System Status” in the con-
trol panel will show “Idle” and the “Temperature” box will be
green (Fig. 2, bottom middle).
7. Place a black XFM-1 low fluorescence mat inside the imaging
chamber with the matt side facing upward (the black mat is
required for bioluminescence and fluorescence imaging but
may have been removed by others when doing trans-
illumination imaging).
8. Start the anesthesia/isoflurane system—this should be
connected to the IVIS and to an induction chamber. Make
sure that the system receives O2 (for example from an open
O2 tank or oxygen generator) and that the isoflurane level is
full. If not then these will need to be filled/replaced before
proceeding.
9. Turn on the O2 supply and the waste gas scavenger.
10. Transfer 3–5 mice to the induction chamber and close it tightly
(see Note 15).
Fig. 2 IVIS Acquisition Control panel in the Living Image Software. An example of the image settings for
acquisition of bioluminescence is shown. In this case, exposure time of 1 min, binning of 16, F/stop of 1 and
field of view E is selected for imaging of the whole body after compound treatment (see Table 1)
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11. Initiate anesthesia using 1.5 L per minute O2 with 4% isoflur-
ane. Ensure that the flow of isoflurane is toward the induction
chamber.
12. Inject 150 mg/kg beetle luciferin subcutaneously (using 10 μL
of the 15 mg/mL stock per gram of mouse) and record the
time of luciferin injection (see Notes 16 and 17).
13. Mice are usually imaged from 10 to 12 min after luciferin
injection (see Note 18)—while waiting for this time to pass
choose the appropriate predetermined settings on the Living
Image software control panel (Fig. 2, top and left panels). For
imaging in this model and using subcutaneous injection of
luciferin we use the settings shown in Table 1. The time of
image acquisition and sequence of images are shown below:
Time of image acquisition: start 12 min after luciferin injection
(the bioluminescent signal plateau is from 15 to 20 min).
Sequence of imaging: (1) one ventral whole body image,
(2) one side whole body image (with spleen facing
upward), mice are then imaged individually for (3) one
dorsal head image, (4) one side head image (see Note 19).
Ensure that the “Overlay” and “Alignment Grid” boxes
(middle of control panel) are ticked.
14. Using a cotton swab, gently apply Lacri-lube ocular lubricant
directly to the eyes of each mouse to prevent eyes from
drying out.
15. Transfer mice to the IVIS imaging chamber and place each
mouse with its nose in a nose cone; ensure that unused nose
pieces are closed with black plugs (see Note 21).
Table 1
Image acquisition settings used for the T. b. brucei GVR35-VSL2 imaging model
Field of view (FOV) Imaging mode Exposure time Binning f/stop Excitation
Untreated mice/whole body
E Luminescence 1 s Small (4) 1 Block
Untreated mice/head
A Luminescence 1 s Small (4) 1 Block
Treated mice/whole body (see Note 20)
E Luminescence 1 min Large (16) 1 Block
Treated mice/head
A Luminescence 1 min Large (16) 1 Block
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16. Place light absorbing dividers between mice to avoid signal
contamination (see Note 22).
17. Reduce isoflurane to 1.5% and direct the flow of anesthetic to
the IVIS system (using the ON/OFF switch or turning the
knob toward the IVIS system—this mechanism depends on the
system being used).
18. Acquire images by clicking “Acquire” on bottom left side of
the control panel.
19. Upon acquisition of the first image after initialization the
software will offer the option of auto-saving and allow selection
of the location for the saved files. Select auto-save.
20. Various input boxes are available to record data, such as time
point, mouse strain and general comments. Useful information
to record are the treatment group, mouse numbers, time-
point, type of image (e.g., ventral body or dorsal head), and
the luciferin injection time (this allows easier selection later of




1. Dilute 4 μL of blood (taken via a tail vein venipuncture using a
lancet or needle) in 16 μL of 0.9% ammonium chloride to lyse
the blood cells. Determine parasite density in blood by count-
ing on a hemocytometer.
3.2.4 In Vivo Compound
Treatments
1. The optimal vehicle and dosing route for drug treatment
should be determined in advance (see Note 23). Diminazene
aceturate is administered intraperitoneally in water as a single
dose at 40 mg/kg in distilled water.
2. Prepare the vehicle and compounds one day before treatment
(if compound stability allows for this). Diminazene aceturate
should be prepared fresh on the day of treatment and filtered
using a 0.22 μm syringe filter.
3. Store treatment compounds as aliquots at 4 C during treat-
ment regime. Bring to room temperature and mix well before
each treatment.
4. Treatment starts at day 7 (stage 1 model) or day 21 (stage
2 model) after infection (seeNote 13); mice should be weighed
and dosed according to weight (see Note 24).
5. If required take blood samples for pharmacokinetic analysis as
described in Subheading 3.2.5.
6. Weigh mice and monitor daily for adverse effects of infection or
treatment.




1. Blood sampling (site, volume and frequency) should be done in
accordance with animal welfare legislation and as approved by
the relevant Ethics Committee. If needed this may require
additional animals or alternating bleeding of mice to minimize
stress and stay within ethical guidelines.
2. Prepare labeled collection tubes in advance.
3. Heat mice in a thermostatically controlled warm air box to
dilate blood vessels (in this case, the tail vein).
4. Disinfect the blood sampling site by washing with an antimi-
crobial solution (e.g., 2% water-based chlorhexidine).
5. Restrain the mouse and puncture the skin and underlying
blood vessel using a needle or lancet.
6. Withdraw the appropriate amount of blood into a heparinized
collection tube.
7. Stop blood flow by applying finger pressure on the site for
~30 s and return the animal to its cage.
8. Mix the blood in the collection tube, transfer the appropriate
volume(s) to fresh nonheparinized tubes and freeze at 20 C
for pharmacokinetic analysis.
3.2.6 End Point Imaging 1. For the stage 1 model the end point may range between day
14 and 21. For the stage 2model the untreated controls should
be culled at day 28–30 postinfection (see Note 25), while
diminazene aceturate controls and treatment group mice will
be culled upon relapse of parasitemia in blood. If no relapse
occurs in the treated group, mice may be monitored for longer
periods until a defined end point (e.g., day 100 or day 180).
2. At the chosen end point image mice as described in Subheading
3.2.2.
3. Cull mice by cervical dislocation or exposure to a rising con-
centration of CO2 (the latter is advised if perfusion of mice is
required).
4. Optional: Perfuse mice with PBS-G to remove all blood from
the brain for quantification of the brain-resident parasites.
5. Remove the brain and place into a petri dish; add 100 μL of
beetle luciferin (15 mg/mL stock) onto the brain surface and
image ex vivo, using 1-min exposure time, large binning and f
stop 1. The signal peaks ~8 min after luciferin application;
however, images are taken continuously up to 10 min after
application.
6. Optional: Rinse brains with PBS, snap-freeze in liquid nitrogen
and store at 80 C for qPCR analysis [13, 16].
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3.3 Image Analysis 1. Analyze images using Living Image software from PerkinElmer
as described in the software manual.
4 Notes
1. All animal procedures described in this chapter are in accor-
dance with the guidelines of the UK Home Office under
authorized Home Office licenses and approved by the relevant
Animal Welfare and Ethics Committees. Its implementation in
other laboratories will require approval from relevant govern-
ment and institutional committees before commencing work.
2. T.b.b. GVR35-VSL2 lines can be obtained from the
corresponding author as culture stabilates or as blood stabilates
for infection of donor mice.
3. Outbred CD1 (ICR) mice tolerate infection with T. brucei
GVR35 well. Pilot studies with inbred BALB/c mice indicated
that this strain is more susceptible to secondary infections when
infected with T. brucei.
4. The GVR35 imaging model described here makes use of bio-
luminescence imaging (Subheading 3.2.2) with the IVIS spec-
trum imaging system (PerkinElmer) and Living Image analysis
software (Subheading 3.3); the model can also be adapted for
use with other in vivo small animal imaging systems and analysis
software.
5. In vitro culturing will affect the virulence of T. brucei GVR35;
use of F1 blood stabilates for the generation of new blood
stabilate working stocks is recommended.
6. Cells may grow very slowly after the first passage. Some cells
will die while others continue to divide resulting in no net
increase in cells in the first couple of days. The culture will
recover and grow normally (~three fold overnight) between
1 and 2 weeks after thawing of the stabilate. Cells will start
growing faster (growth of fivefold overnight) over time but
may also become more virulent so this should be avoided to
ensure reproducibility of the model.
7. The cells will start dying from 1.5–2 106 cells/mL so are best
kept at a density below 1  106 cells/mL.
8. Mice will develop parasitemia at different times and parasites
harvested from blood may vary in their infectivity. It is there-
fore advised to infect twomice for harvesting of parasites and to
make two sets of stabilates for later selection of the set which
results in the most reliable infections (Subheadings 3.1.2 and
3.1.3).
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9. Single-use needles and lancets should be used to avoid contam-
ination and additional injury to mice.
10. It is important to harvest parasites from mice while parasitemia
is increasing. Once parasitemia has reached its peak and
decreases again the parasites will be less infective. Harvest
parasites when parasitemia is in the range of 5  106–
1.5  107 parasites/mL of blood.
11. Parasites will be harvested from donor mice during their first
peak of parasitemia and then used to infect experimental mice
(designated as day 0). Imaging and treatment of mice is usually
done from day 7 (stage 1 model) or day 21 (stage 2 model)
after infection and should ideally fall on a convenient day that
will also allow for preparation of compounds one day in
advance. For example, our blood straws produce an infection
in donor mice with the first peak of parasitemia developing
4–5 days postinfection. By infecting donor mice on a Thursday
blood and parasites can usually be harvested on the following
Tuesday for infection of experimental mice. This allows for
preparation of compounds on Monday and imaging as well as
start of compound treatment on Tuesday.
12. We routinely set mice up in groups of six per treatment with
three diminazene aceturate-treated controls and three
untreated controls. These animal numbers have been deter-
mined using a power analysis with variables estimated from
previous experiments. The variables and calculated group
sizes may change depending on the mice used, the biolumines-
cence of the parasites and sensitivity of the imaging systems.
Pilot studies should be performed when setting up a new
model to estimate the variables for power analysis.
13. The GVR35mouse model mimics stage 1 disease at day 7 post-
infection. By day 21 the parasites become established in the
CNS and infections can only be cured by compounds active in
the brain [16, 17]. For screening in stage 2, mice should always
be treated after 21 days of infection. Treatment can also be
delayed by 1 or 2 days if required for logistical reasons (e.g.,
day 8 or 9 for stage 1 and day 22 or 23 for stage 2) with
subsequent delay in the posttreatment imaging time points.
14. The imaging schedule should be determined in advance and
will depend on what is feasible and what analysis is to be done.
To analyze in vivo kill kinetics daily imaging after treatment
may be needed. For stage 1, imaging usually starts on day 7 and
can be done daily afterward up to day 14 (e.g., day 7, 8, 9, 10,
14). For stage 2, imaging usually starts at day 21 and is done
weekly, or later (usually after day 63), 2-weekly intervals fol-
lowing start of treatment (e.g., day 21, 28, 35, 42, 49, etc.).
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15. The number of animals to be imaged will depend on the IVIS
imaging system being used. We prefer to image three mice at a
time to allow space between mice.
16. It is preferable to inject luciferin subcutaneously or intraperito-
neally. While subcutaneous injection results in a slightly lower
signal compared with intraperitoneal injection it has a longer
and flatter signal kinetics making it more suitable for taking
multiple images of the whole body or head. Furthermore, there
is a higher risk of failure for intraperitoneal injection (where
injection is placed into a site other than the peritoneal cavity,
such as the lumen of the stomach or bowel, or injection is
subcutaneous, retroperitoneal or intravascular), particularly in
trypanosome-infected mice where spleens are enlarged. A
failed injection may reduce the luciferin concentration in tis-
sues resulting in lower bioluminescence or result in death.
17. Luciferin can be injected once the animal is anesthetized; how-
ever, this will alter the kinetics of the signal compared with an
animal that is awake. This should be taken into account when
establishing acquisition timings and setting.
18. Imaging acquisition settings and the timing of imaging after
luciferin injection need to be determined in advance. This will
depend on the site of luciferin injection, strength of the signal,
and location of the signal. To establish the imaging start time
calculate a kinetic curve during a pilot study—this is done by
taking multiple images over time and determining when the
signal peaks and falls.
19. The mouse to be imaged is moved to the middle nose cone
while the other two remain on outer nose cones. For head
images the “Field of view (FOV)” on the IVIS acquisition
panel should be set on A—this increases resolution by moving
the stage upward but will only allow imaging of the middle
mouse (e.g., for the IVIS spectrum FOV A is 3.9  3.9 cm).
Once head images of the middle mouse are completed it is
transferred to a holding box and another mouse is moved to
the middle for imaging of head (any open nose cones should be
blocked with black plugs as mice are transferred from the
imaging chamber).
20. Mice may have low bioluminescence signal after treatment with
a trypanocidal compound; to detect these low signals increase
the exposure time and the binning. In untreated mice, or mice
with relapsed parasitemia, signal may be saturated at high
exposure and binning; in these instances the exposure time
and binning should be decreased or the F/stop increased.
21. Transparent nose cones ensure gas delivery to individual mice
from the anesthesia manifold. Black rubber plugs seal unused
ports of the anesthesia manifold. Nose cones and plugs should
be provided with the IVIS gas anesthesia system.
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22. XMD-2 manifold dividers are available in different heights and
can be purchased from PerkinElmer or may have been provided
with the IVIS system. We cut dividers from black Lexan plastic
sheets. In cases where high signal from amouse still spills over to
other mice with low signal it may be necessary to re-image mice
separately (e.g., this may occur when parasites have recrudesced
in one mouse while others remain clear of parasite signal).
23. The vehicle and dosing regimen for compounds should be
determined in advance and tested for toxicity in uninfected
mice before used for treatment in the T. b. brucei infection
model.
24. Compound administration should be done in volumes as spe-
cified in the appropriate animal project license or as recom-
mended by animal research advisory boards. For example for
oral dosing it is considered good practice to administer com-
pounds in 10 mL vehicle/kg of mouse [18].
25. CD1 mice infected with T. b. brucei GVR35 may develop
symptoms related to infection of the CNS such as hind-leg
paralysis and paresis. This usually occurs from day 28–35 post-
infection. To avoid these adverse effects from developing
untreated mice should be culled at day 28–30 postinfection
(e.g., after the imaging session, 7 days after start of treatment)
or when symptoms become visible.
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